Drug Use Investigation for LAMICTAL
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01376180 |
Recruitment Status
:
Completed
First Posted
: June 20, 2011
Last Update Posted
: November 9, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Epilepsy | Drug: Lamotrigine |
Study Type : | Observational |
Actual Enrollment : | 3000 participants |
Time Perspective: | Prospective |
Official Title: | Drug Use Investigation for LAMICTAL |
Study Start Date : | December 2008 |
Actual Primary Completion Date : | August 2016 |
Actual Study Completion Date : | August 2016 |

Group/Cohort | Intervention/treatment |
---|---|
Subjects prescribed lamotrigine tablet
Subjects with epilepsy prescribed lamotrigine tablet during study period
|
Drug: Lamotrigine
Administered according to the prescribing information in the locally approved label by the authorities
|
- The number of adverse events in Japanese subjects with epilepsy treated with lamotrigine tablet [ Time Frame: 6 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Senior |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Subjects with epilepsy having the following seizure types.
- partial seizures (including secondary generalized seizures)
- tonic-clonic seizures
- generalized seizures of Lennox-Gastaut syndrome
Inclusion Criteria:
- Subjects with epilepsy having the following seizure types.
- Partial seizures (including secondary generalized seizures)
- Tonic-clonic seizures
- Generalized seizures of Lennox-Gastaut syndrome
Exclusion Criteria:
- None

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01376180
Study Director: | GSK Clinical Trials | GlaxoSmithKline |
Publications:
Responsible Party: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT01376180 History of Changes |
Other Study ID Numbers: |
112727 |
First Posted: | June 20, 2011 Key Record Dates |
Last Update Posted: | November 9, 2016 |
Last Verified: | November 2016 |
Additional relevant MeSH terms:
Lamotrigine Anticonvulsants Calcium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Excitatory Amino Acid Antagonists |
Excitatory Amino Acid Agents Neurotransmitter Agents Physiological Effects of Drugs Voltage-Gated Sodium Channel Blockers Sodium Channel Blockers |